300 related articles for article (PubMed ID: 11019977)
21. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
Weber AA; Schrör K
Blood; 2001 Sep; 98(5):1619-21. PubMed ID: 11520817
[TBL] [Abstract][Full Text] [Related]
22. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
Harder S; Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Glusa E; Mascelli MA; Marciniak SJ; Just A; Lösche W; Breddin HK
Thromb Res; 2001 Apr; 102(1):39-48. PubMed ID: 11323013
[TBL] [Abstract][Full Text] [Related]
23. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Lisman T; Moschatsis S; Adelmeijer J; Nieuwenhuis HK; De Groot PG
Blood; 2003 Mar; 101(5):1864-70. PubMed ID: 12411291
[TBL] [Abstract][Full Text] [Related]
24. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Goto S; Tamura N; Ishida H
J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
[TBL] [Abstract][Full Text] [Related]
26. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.
Haga JH; Jennings LK; Slack SM
Ann Biomed Eng; 2002; 30(10):1262-72. PubMed ID: 12540202
[TBL] [Abstract][Full Text] [Related]
29. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
Caron A; Théorêt JF; Mousa SA; Merhi Y
J Cardiovasc Pharmacol; 2002 Aug; 40(2):296-306. PubMed ID: 12131559
[TBL] [Abstract][Full Text] [Related]
30. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
[TBL] [Abstract][Full Text] [Related]
31. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
Kanemitsu S; Nishikawa M; Onoda K; Shimono T; Shimpo H; Yazaki A; Tanaka K; Shiku H; Yada I
J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
[TBL] [Abstract][Full Text] [Related]
33. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Ito H; Miyakoda G; Mori T
Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
[TBL] [Abstract][Full Text] [Related]
34. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
Reiter RA; Mayr F; Blazicek H; Galehr E; Jilma-Stohlawetz P; Domanovits H; Jilma B
Blood; 2003 Dec; 102(13):4594-9. PubMed ID: 12920042
[TBL] [Abstract][Full Text] [Related]
35. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
Speich HE; Earhart AD; Hill SN; Cholera S; Kueter TJ; Smith JN; White MM; Jennings LK
J Thromb Haemost; 2009 Jun; 7(6):983-91. PubMed ID: 19548907
[TBL] [Abstract][Full Text] [Related]
36. Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.
Salanova B; Choi M; Rolle S; Wellner M; Luft FC; Kettritz R
J Biol Chem; 2007 Sep; 282(38):27960-9. PubMed ID: 17644514
[TBL] [Abstract][Full Text] [Related]
37. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.
Dickfeld T; Ruf A; Pogatsa-Murray G; Müller I; Engelmann B; Taubitz W; Fischer J; Meier O; Gawaz M
Thromb Res; 2001 Jan; 101(2):53-64. PubMed ID: 11342206
[TBL] [Abstract][Full Text] [Related]
38. Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?
Schumann A; Bucha E; Nowak G
Semin Thromb Hemost; 2005; 31(4):476-81. PubMed ID: 16149027
[TBL] [Abstract][Full Text] [Related]
39. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
40. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
